Who
Richard Malamut
Director
Company insider
Files Form 4 as: Director, Pelthos Therapeutics; EVP and Chief Medical Officer, Collegium Pharmaceutical.
In numbers
- Trades disclosed
- 32
- Buys
- 1
- Sells
- 1
- Bought
- $9,776
- Sold
- $25K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 1 Apr 2019
- Last trade
- 2 Apr 2026
- Last filed
- 6 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Apr 2026filed 6 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $6,359310 at $20.51 | filing |
| 2 Apr 2026filed 6 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $5,981280 at $21.36 | filing |
| 2 Apr 2026filed 6 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $6,358310 at $20.51 | filing |
| 2 Apr 2026filed 6 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $5,981280 at $21.36 | filing |
| 13 Nov 2025filed 1 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —2,454 at $0.00 | filing |
| 13 Nov 2025filed 1 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —2,454 at $0.00 | filing |
| 2 Jul 2025filed 1 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —19,108 at $0.00 | filing |
| 2 Jul 2025filed 1 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —19,108 at $0.00 | filing |
| 2 Jul 2025filed 7 Jul 2025 | PTHS Pelthos Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —19,108 | filing |
| 2 Jul 2025filed 7 Jul 2025 | PTHS Pelthos Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —58,230 | filing |
| 13 Nov 2024filed 15 Nov 2024 | PTHS Pelthos Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —24,533 | filing |
| 12 Sep 2024filed 16 Sep 2024 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Bought | $9,77610,400 at $0.94 | filing |
| 14 Jun 2024filed 1 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —6,450 at $0.00 | filing |
| 14 Jun 2024filed 1 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —6,450 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | PTHS Pelthos Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —64,498 | filing |
| 10 Feb 2022filed 14 Feb 2022 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code A | —36,750 at $0.00 | filing |
| 10 Feb 2022filed 14 Feb 2022 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code A | —6,256 | filing |
| 10 Feb 2022filed 14 Feb 2022 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code F | $79K4,462 at $17.63 | filing |
| 10 Feb 2022filed 14 Feb 2022 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code F | $32K1,838 at $17.63 | filing |
| 1 Apr 2021filed 5 Apr 2021 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code F | $73K3,119 at $23.38 | filing |
News
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Downgraded by Zacks Research to Strong SellPTHS · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Richard Malamut; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.